Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This partially randomized phase I/II trial studies the side effects and best dose of
enzalutamide and mifepristone when given together and to see how well they work in treating
patients with metastatic hormone resistant prostate cancer. Androgens can cause the growth of
prostate cancer cells. Antihormone therapy, such as enzalutamide and mifepristone, may lessen
the amount of androgens made by the body. It is not yet known whether enzalutamide is more
effective with or without mifepristone in treating patients with prostate cancer.